Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 622-627

  Dirou, S ^a,b   Malard, F ^b,c,d   Chambellan, A ^a,b   Chevallier, P ^c   Germaud, P ^a   Guillaume, T ^c   Delaunay, J ^c   Moreau, P ^b,c,d   Delasalle, B ^a,b,d   Lemarchand, P ^a,b,d   Mohty, M ^a,b,c,d  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d L INSTITUT DU THORAX   (France)

Author keywords

ATG; pulmonary function; reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ADULT; AIRWAY OBSTRUCTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; AGED; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; HEMATOLOGIC DISEASES; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASES; LUNG FUNCTION TEST; LYMPHOCYTE DEPLETION; MIDDLE AGED; PROCEDURES; STEM CELL TRANSPLANTATION; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 84900302697     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.15     Document Type: Article

References (44)

1. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261-1269
2. Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant 2010; 16: 53-61
3. Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C et al. Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 223-230
4. Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005; 35: 1195-1200
5. Soule BP, Simone NL, Savani BN, Ning H, Albert PS, Barrett AJ et al. Pulmonary function following total body irradiation (with or without lung shielding) and allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 2007; 40: 573-578
6. Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica 2007; 92: 558-561
7. Duncker C, Dohr D, Harsdorf S, Duyster J, Stefanic M, Martini C et al. Non-infectious lung complications are closely associated with chronic graft-versus-host disease: A single center study of incidence, risk factors and outcome. Bone Marrow Transplant 2000; 25: 1263-1268
8. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: Diagnosis, monitoring, prevention, and treatment. Semin Hematol 2012; 49: 15-24
9. Martin PJ, Chien JW. What we know and mostly do not know about bronchiolitis obliterans syndrome. Bone Marrow Transplant 2012; 47: 1-4
10. Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Muller KG. Bronchiolitis obliterans after allo-SCT: Clinical criteria and treatment options. Bone Marrow Transplant 2012; 47: 1020-1029
11. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231
12. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 2007; 110: 4606-4613
13. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177
14. Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2010; 45: 786-788
15. Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versushost disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 28-34
16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
17. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218
18. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664
19. American Thoracic Society. Recommendations for a standard technique. Single breath carbon monoxide diffusing capacity (transfer factor). Am Rev Respir Dis 1987; 136: 1299-1307
20. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
21. Frisk P, Arvidson J, Hedenstrom H. A longitudinal study of pulmonary function after stem cell transplantation, from childhood to young adulthood. Pediatr Blood Cancer 2012; 58: 775-779
22. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821
23. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, Aubry MC et al. Pulmonary complications in adult blood and marrow transplant recipients: Autopsy findings. Chest 2005; 128: 1385-1392
24. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763
25. Krejci M, Brychtova Y, Doubek M, Tomiska M, Navratil M, Racil Z et al. Long-term results of allogeneic hematopoietic stem cell transplantation after reducedintensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Neoplasma 2011; 58: 406-414
26. Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T et al. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies. Biol Blood Marrow Transplant 2011; 17: 1698-1703
27. Milano F, Au MA, Boeckh MJ, Deeg HJ, Chien JW. Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 703-709
28. Lahzami S, Schoeffel RE, Pechey V, Reid C, Greenwood M, Salome CM et al. Small airways function declines after allogeneic haematopoietic stem cell transplantation. Eur Respir J 2011; 38: 1180-1188
29. Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer 2001; 92: 1949-1958
30. Santo Tomas LH, Loberiza Jr FR, Klein JP, Layde PM, Lipchik RJ, Rizzo JD et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161
31. Kelsey CR, Horwitz ME, Chino JP, Craciunescu O, Steffey B, Folz RJ et al. Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: An assessment of risk factors. Int J Radiat Oncol Biol Phys 2011; 81: 812-818
32. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565
33. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-434
34. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970
35. Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T et al. Features of Epstein-Barr virus (EBV) reactivation after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011; 25: 932-938
36. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: Long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATGFresenius. Blood 2011; 117: 6375-6382
37. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: Report on baseline data from the Chronic GVHD Consortium. Blood 2011; 117: 4651-4657
38. Ginsberg JP, Aplenc R, McDonough J, Bethel J, Doyle J, Weiner DJ. Pre-transplant lung function is predictive of survival following pediatric bone marrow transplantation. Pediatr Blood Cancer 2010; 54: 454-460
39. Patriarca F, Skert C, Sperotto A, Damiani D, Cerno M, Geromin A et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004; 33: 751-758
40. Chang PM, Chiou TJ, Yen CC, Hsiao LT, Liu JH, Chen PM. Diffusion capacity predicts long-term survival after allogeneic bone marrow transplantation for acute lymphoblastic leukemia. J Chin Med Assoc 2008; 71: 234-240
41. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia in adults: Significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867-872
42. Chiou TJ, Tung SL, Wang WS, Tzeng WF, Yen CC, Fan FS et al. Pulmonary function changes in long-term survivors of chronic myelogenous leukemia after allogeneic bone marrow transplantation: A Taiwan experience. Cancer Invest 2002; 20: 880-888
43. Lund MB, Brinch L, Kongerud J, Boe J. Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide. Eur Respir J 2004; 23: 901-905
44. Crawford SW, Pepe M, Lin D, Benedetti F, Deeg HJ. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995; 152: 690-695.